Q4 Earnings Estimate for LRMR Issued By Leerink Partnrs

Key Points

• Leerink Partners has issued a Q4 2026 EPS estimate for Larimar Therapeutics of ($0.59) per share, while the consensus for the full year is currently ($1.15).
• Larimar Therapeutics recently beat the consensus earnings estimate for the previous quarter, reporting ($0.41) EPS compared to the expected ($0.47).
• The stock has received multiple "buy" ratings and has a current average target price of $18.43, following recent modifications in holdings by institutional investors.

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Analysts at Leerink Partnrs issued their Q4 2026 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a research note issued on Thursday, August 14th. Leerink Partnrs analyst J. Park expects that the company will post earnings of ($0.59) per share for the quarter. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share.

A number of other analysts also recently issued reports on LRMR. Wedbush decreased their price target on Larimar Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, June 24th. JMP Securities decreased their price target on Larimar Therapeutics from $22.00 to $18.00 and set a "market outperform" rating for the company in a report on Friday, August 15th. Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. Finally, Guggenheim reaffirmed a "buy" rating and set a $26.00 price objective on shares of Larimar Therapeutics in a report on Tuesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $18.43.

Larimar Therapeutics Stock Performance

NASDAQ LRMR traded up $0.2850 during trading on Monday, reaching $3.9750. 1,051,579 shares of the company's stock were exchanged, compared to its average volume of 1,081,461. The stock has a market cap of $329.05 million, a P/E ratio of -2.55 and a beta of 0.93. The company has a 50 day moving average price of $3.36 and a two-hundred day moving average price of $2.79. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $9.50.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.06.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LRMR. Wells Fargo & Company MN raised its holdings in Larimar Therapeutics by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 19,657 shares of the company's stock worth $76,000 after purchasing an additional 6,701 shares in the last quarter. Envestnet Asset Management Inc. grew its position in shares of Larimar Therapeutics by 12.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company's stock valued at $137,000 after purchasing an additional 3,877 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Larimar Therapeutics by 45.1% in the fourth quarter. Renaissance Technologies LLC now owns 513,542 shares of the company's stock valued at $1,987,000 after purchasing an additional 159,700 shares during the last quarter. Barclays PLC boosted its position in Larimar Therapeutics by 17.3% during the fourth quarter. Barclays PLC now owns 70,425 shares of the company's stock worth $273,000 after acquiring an additional 10,393 shares during the last quarter. Finally, XTX Topco Ltd boosted its position in Larimar Therapeutics by 316.3% during the fourth quarter. XTX Topco Ltd now owns 63,810 shares of the company's stock worth $247,000 after acquiring an additional 48,481 shares during the last quarter. 91.92% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Larimar Therapeutics

In other Larimar Therapeutics news, Director James E. Flynn bought 9,375,000 shares of the firm's stock in a transaction dated Thursday, July 31st. The stock was acquired at an average price of $3.20 per share, for a total transaction of $30,000,000.00. Following the completion of the purchase, the director owned 9,538,945 shares of the company's stock, valued at approximately $30,524,624. This represents a 5,718.38% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.50% of the company's stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.